Danijela Gnjidic

Dr. Danijela Gnjidic


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
DGDanijela Gnjidic
Danijela Gnjidic
SHSarah N. Hilmer
Sarah N. Hilmer
FBFiona M. Blyth
Fiona M. Blyth
VNVasi Naganathan
Vasi Naganathan
LWLouise Waite
Louise Waite
DCDavid G. Le Couteur
David G. Le Couteur

1 February 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
DGDanijela Gnjidic
Danijela Gnjidic
SHS N Hilmer
S N Hilmer
FBF M Blyth
F M Blyth
VNV Naganathan
V Naganathan
RCR G Cumming
R G Cumming
DCD G Le Couteur
D G Le Couteur


1 May 2012 in Clinics in Geriatric Medicine
Verified
Journal Article
Closed access
DGDanijela Gnjidic
Danijela Gnjidic
DCDavid G. Le Couteur
David G. Le Couteur
LKLisa Kouladjian
Lisa Kouladjian
SHSarah N. Hilmer
Sarah N. Hilmer

16 July 2009 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
DGDanijela Gnjidic
Danijela Gnjidic
RCRobert G. Cumming
Robert G. Cumming
DCDavid G. Le Couteur
David G. Le Couteur
DHDavid J. Handelsman
David J. Handelsman
VNVasi Naganathan
Vasi Naganathan
SHSarah N. Hilmer
Sarah N. Hilmer
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Inappropriate medication use is common among the elderly.• Use of medications with anticholinergic and sedative properties is associated with functional impairments in older people.• Exposure to anticholinergic and sedative medications, measured with Drug Burden Index that includes the principles of dose–response and maximal effect, was associated with impairment in physical and cognitive function in two studies of older people in the USA. WHAT THIS STUDY ADDS • We evaluated Drug Burden Index in an Australian population of community‐dwelling older men, The Concord Health and Ageing in Men Project that enrolled a random sample of community‐dwelling men aged ≥70 years living in Sydney, Australia.• In this population, increasing Drug Burden Index was associated with objective impairments of physical performance and functional status.• The Drug Burden Index has broad applicability regardless of healthcare system, prescribing practices, gender or country.AIMS: This study evaluated the associations of physical performance and functional status measures with the Drug Burden Index in older Australian men. The Drug Burden Index is a measure of total exposure to anticholinergic and sedative medications that incorporates the principles of dose–response and maximal effect.METHODS: A cross‐sectional survey was performed on community‐dwelling older men enrolled in The Concord Health and Ageing in Men Project, Sydney, Australia. Outcomes included chair stands, walking speed over 6 m, 20‐cm narrow walk speed, balance, grip strength and Instrumental Activities of Daily Living score (IADLs).RESULTS: The study population consisted of 1705 men (age 76.9 ± 5.5 years). Of the 1527 (90%) participants who reported taking medications, 21% were exposed to anticholinergic and 13% to sedative drugs. The average Drug Burden Index in the study population was 0.18 ± 0.35. After adjusting for confounders (sociodemographics, comorbidities, cognitive impairment, depression), Drug Burden Index was associated with slower walking speed (P < 0.05), slower narrow walk speed (P < 0.05), balance difficulty (P < 0.01), grip weakness (P < 0.01) and poorer performance on IADLs (P < 0.05). Associations with physical performance and function were stronger for the sedative than for the anticholinergic component of the Drug Burden Index.CONCLUSIONS: Higher Drug Burden Index is associated with poorer physical performance and functional status in community‐dwelling older Australian men. The Drug Burden Index has broad applicability as a tool for assessing the impact of medications on functions that determine independence in older people.

15 December 2011 in BMJ
Verified
Journal Article
Open access
PDF file
FSFiona F Stanaway
Fiona F Stanaway
DGDanijela Gnjidic
Danijela Gnjidic
FBFiona M Blyth
Fiona M Blyth
DCD. G. L. Couteur
D. G. L. Couteur
VNVasi Naganathan
Vasi Naganathan
RCRobert G Cumming
Robert G Cumming
Objective To determine the speed at which the Grim Reaper (or Death) walks. Design Population based prospective study. Setting Older community dwelling men living in Sydney, Australia. Participants 1705 men aged 70 or more participating in CHAMP (Concord Health and Ageing in Men Project). Main outcome measures Walking speed (m/s) and mortality. Receiver operating characteristics curve analysis was used to calculate the area under the curve for walking speed and determine the walking speed of the Grim Reaper. The optimal walking speed was estimated using the Youden index (sensitivity+specificity−1), a common summary measure of the receiver operating characteristics curve, and represents the maximum potential effectiveness of a marker. Results The mean walking speed was 0.88 (range 0.15-1.60) m/s. The highest Youden index (0.293) was observed at a walking speed of 0.82 m/s (2 miles (about 3 km) per hour), corresponding to a sensitivity of 63% and a specificity of 70% for mortality. Survival analysis showed that older men who walked faster than 0.82 m/s were 1.23 times less likely to die (95% confidence interval 1.10 to 1.37) than those who walked slower (P=0.0003). A sensitivity of 1.0 was obtained when a walking speed of 1.36 m/s (3 miles (about 5 km) per hour) or greater was used, indicating that no men with walking speeds of 1.36 m/s or greater had contact with Death. Conclusion The Grim Reaper’s preferred walking speed is 0.82 m/s (2 miles (about 3 km) per hour) under working conditions. As none of the men in the study with walking speeds of 1.36 m/s (3 miles (about 5 km) per hour) or greater had contact with Death, this seems to be the Grim Reaper’s most likely maximum speed; for those wishing to avoid their allotted fate, this would be the advised walking speed.